CDKN2B and cancer: Apart from the potential oncogenic role of CDKN2B-AS1 in BC, all the above mechanisms could support CDKN2B-AS1 upregulation in breast cancer in part as an adaptive response to DNA and cellular damage during the tumorigenesis process, which could explain the association of high expression of this type of lncRNA with survival and cancer grade; the findings were validated by the same results from the TCGA data set.